Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

January 31, 2018

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraordinary general meeting, whereby the company will receive approximately SEK 88 million before transaction costs.


The issue proceeds will primarily be invested in the development of new drug candidates, based on Xspray Pharma’s HyNap-platform. The share issue will be fully subscribed in accordance with separate agreements with the selected investors. Shareholders representing approximately 67.2 percent of Xspray Pharma’s shares have undertaken to vote in favor of the share issue at an extraordinary general meeting.

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. The company’s shares are admitted to trading on Nasdaq First North.

Vinge’s team consists of Dain Hård Nevonen, Sabina Börjesson, Nils Fredrik Dehlin and Ramin Baradaran.

Related

Vinge represents Sedana Medical AB in the acquisition of Innovatif Cekal

Vinge has represented Sedana Medical AB (publ) in connection with the acquisition of Innovatif Cekal. Innovatif Cekal, based in Klang near Kuala Lumpur, Malaysia, is a manufacturer of medical devices. This acquisition enhances Sedana Medical's control over its supply chain and improves profitability through reduced cost of goods.
January 22, 2025

Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB

Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.
January 20, 2025

Vinge advises Platzer in conjunction with the sale of a school property in Gothenburg

Vinge has advised Platzer Fastigheter AB in connection with the sale of a school property situated in Södra Änggården, Gothenburg. The property, which was sold as a corporate transaction, has a value of SEK 552 million. The sale is part of Platzer's strategy to develop and optimise its property portfolio.
January 17, 2025